ERC-AG-LS7
ERC-AG-LS7
Programme: H2020
89 projects · €209,113,287 total EU contribution (project-level) · 102 participating organizations · 18 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€209,113,287
Countries active
Participant organizations by country (headquarters in CORDIS).
- Italy (19)
- Germany (16)
- UK (13)
- Spain (12)
- Netherlands (11)
- France (5)
- CH (4)
- SE (4)
- NO (3)
- BE (2)
- CY (2)
- DK (2)
- FI (2)
- IL (2)
- EL (1)
- HU (1)
- IE (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM6 projects · FR
- KU Leuven4 projects · BE
- ERASMUS MC3 projects · NL
- HELSINGIN YLIOPISTO3 projects · FI
- UEDIN3 projects · UK
- UNIVERSITY COLLEGE LONDON3 projects · —
- Leiden University Medical Center2 projects · NL
- CSIC2 projects · ES
- GERMAN CANCER RESEARCH CENTER2 projects · DE
- HSR2 projects · IT
- INGM2 projects · IT
- IRFMN2 projects · IT
Projects
Page 1 of 9
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Reporter models for the Evaluation of Diseases involving OXidative stress REDOX · 294533 | FP7 | €2,486,524 | €2,486,524 | Details |
Biomechanical diagnostic, pre-planning and outcome tools to improve musculoskeletal surgery BIOMECHTOOLS · 323091 | FP7 | €2,456,400 | €2,456,400 | Details |
P.E.L.E (Protein Energy Landscape Exploration): a la carte drug design tools PELE · 250277 | FP7 | €1,399,999 | €1,399,999 | Details |
Blood regeneration: de novo development of human hematopoietic stem cells DENOVOHSC · 341096 | FP7 | €2,500,000 | €2,500,000 | Details |
ONCOLYTIC HERPESVIRUSES RETARGETED TO CANCER- SPECIFIC RECEPTORS ONCOLYTIC-HERPES · 340060 | FP7 | €2,477,346 | €2,477,346 | Details |
Eradication of tumors by targeting dsRNA selectively to cancer cells and recruitment of the innate immune system TARGETING_CANCER · 249898 | FP7 | €2,054,340 | €2,054,340 | Details |
New and more individualised population-based screening for cardiovascular disease; from a RCT including selfassessments, primary care and coronary artery calcification score to modelling risk-benefit ROBINSCA · 294604 | FP7 | €3,298,999 | €3,298,999 | Details |
Gene Therapy for Inherited Skin Adhesion Disorders GT-SKIN · 269015 | FP7 | €2,210,000 | €2,210,000 | Details |
Quantitative Imaging of Liver Fibrosis and Fibrogenesis LiverFibrosisImaging · 294856 | FP7 | €2,454,604 | €2,454,604 | Details |
GEnetic NEtworks as a tool for anti-CAncer Drug Development GENECADD · 268815 | FP7 | €2,500,000 | €2,500,000 | Details |